57
Participants
Start Date
April 30, 2009
Primary Completion Date
July 31, 2011
Study Completion Date
July 31, 2011
RN6G
intravenous, single dose, dose ranging from 0.3mg/kg up to a maximum of 40 mg/kg.
Placebo
intravenous, single dose with experimental dose.
Jasper Clinic, Inc., Kalamazoo
Jonathan Rowe, MD, Kalamazoo
Ronald VanderLugt, MD, Kalamazoo
CEDRA Clinical Research, LLC, San Antonio
Village Drive Imaging Center, San Antonio
Specialty MRI, San Antonio
Medical Center Ophthalmology Associates, San Antonio
Medical Center Ophthalmology Associates, San Antonio
Retinal Consultants of San Antonio, San Antonio
EZ Pass Rx, Bountiful
Lifetree Clinical Research, Salt Lake City
Rocky Mountain Eye Care Associates, LC, Salt Lake City
Western Neurological Associates, Salt Lake City
Dedicated Phase 1, Phoenix
Retinal Consultants of AZ, Phoenix
Insight Diagnostic Imaging Center, Phoenix
United Medical Imaging, Inglewood
United Medical Research Institute, Inglewood
Amir Hedayati-Rad, MD, Glendale
California Pharmacy and Compounding Center, Newport Beach
Lead Sponsor
Pfizer
INDUSTRY